论文部分内容阅读
目的研究长效哌甲酯片滴定治疗儿童注意缺陷多动障碍(ADHD)合并品行障碍(CD)的效果,观察药物剂量对治疗效果的影响。方法选取2014年1月至2015年1月在本院神经科就诊的儿童注意缺陷多动症并发品行障碍患儿120例,随机分成对照组和试验组各60例,治疗六个月间两组分别接受不同剂量的长效哌甲酯片治疗,在治疗的过程中及实验结束后对试验的结果进行评价。结果 (1)试验组最佳反应发生率明显高于对照组(P<0.05)。(2)试验组在注意多动缺陷障碍筛查量表(SNAP-Ⅳ)中对立违抗、注意力不集中以及冲动多动等多项指标与对照组进行对比,差异具有统计学意义(P<0.05)。(3)在儿童行为量表(CBCL)中,试验组与对照组在交往不良、多动、退缩以及攻击性等六个方面的差异具有统计学的意义(P<0.05)。(4)试验组和对照组副反应发生概率的差异无统计学意义(P>0.05)。结论每天36毫克的长效哌甲酯片对于ADHA相关症状的治疗效果相对比于对照组每天18毫克和54克更为明显,可用于临床用药。
Objective To investigate the effect of long-acting methylphenidate titration in the treatment of children with attention-deficit hyperactivity disorder (ADHD) and conduct disorder (CD), and to observe the effect of drug dosage on the therapeutic effect. Methods A total of 120 children with ADHD and ADHD who were admitted to our department of neurology from January 2014 to January 2015 were randomly divided into control group and trial group of 60 cases each. Different doses of methylphenidate long-term treatment, in the course of treatment and after the end of the experiment to evaluate the results. Results (1) The best response rate of the experimental group was significantly higher than that of the control group (P <0.05). (2) Compared with the control group, there were significant differences between the experimental group and the control group in the antagonism, inattention and impulsive hyperactivity in the attention deficit hyperactivity disorder screening scale (SNAP-Ⅳ) (P < 0.05). (3) In CBCL, the differences between the experimental group and the control group in six aspects of poor communication, hyperactivity, withdrawal and aggressiveness were statistically significant (P <0.05). (4) There was no significant difference in the incidence of side effects between experimental group and control group (P> 0.05). Conclusion 36 mg daily methylphenidate tablets are more effective in treating ADHA-related symptoms compared to 18 mg and 54 g daily in the control group and are useful for clinical use.